Dae Seog Heo

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Vincent A. Miller, Vera Hirsh, Jacques Cadranel et al. · The Lancet Oncology · 2012 · 950 citations

Oncology, Phase 2B/3, Afatinib Versus Placebo +9

Phase I and Pharmacokinetic Study of Genexol-PM, a Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with Advanced Malignancies

Tae‐You Kim, Dong-Wan Kim, Jae‐Yong Chung et al. · Clinical Cancer Research · 2004 · 796 citations

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Sae‐Won Han, Tae‐You Kim, Pil Gyu Hwang et al. · Journal of Clinical Oncology · 2005 · 775 citations · Full text

Elevated TGF-β1 Secretion and Down-Modulation of NKG2D Underlies Impaired NK Cytotoxicity in Cancer Patients

June-Chul Lee, Kyung‐Mi Lee, Dong‐Wan Kim et al. · The Journal of Immunology · 2004 · 536 citations · Full text

Immunology, Nk Cells, Impaired Nk Cytotoxicity +16

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas

Jake June-Koo Lee, Junehawk Lee, Sehui Kim et al. · Journal of Clinical Oncology · 2017 · 498 citations

Pathology, Purpose Histologic Transformation, Genetic Predictors +20